J.R. Devita
Executive Director of Corporate Development and Investor Relations, NuvationBio
Replay available
Nuvation Bio Inc. (NUVB) Q3 2025 Earnings Call
Nuvation Bio Inc. (NYSE: NUVB) Q3 2025 earnings conference call, held 2025-11-03. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Dr. David Hung
Founder, President, and Chief Executive Officer, NuvationBio
Colleen Sjogren
Chief Commercial Officer, NuvationBio
Philippe Sauvage
Chief Financial Officer, NuvationBio
Kaveri Pullman
Analyst, Clear Street
Farzan Haque
Analyst, Jefferies
Sumit Roy
Analyst, Jones Research
Leonid Timishev
Analyst, RBC Capital Markets
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Nuvation Bio Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:05.377 Hello and welcome to NuvationBio's third quarter 2025 financial result 00:00:05.377 -- 00:00:11.063 and corporate update call. Today's call is being recorded and a replay will be available. 00:00:11.063 -- 00:00:14.607 All participants are currently in a listen only mode. 00:00:14.607 -- 00:00:18.351 A brief question and answer session will follow the prepared remarks. 00:00:18.351 -- 00:00:20.433 Now I'd like to turn the call over to J.R. 00:00:20.433 -- 00:00:26.359 Devita, Executive Director of Corporate Development and Investor Relations at NuvationBio. 00:00:26.359 -- 00:00:28.280 Please go ahead. 00:00:28.280 -- 00:00:33.626 Thank you and good afternoon, everyone. Welcome to the innovation bio third quarter 2025 00:00:33.626 -- 00:00:37.110 earnings conference call. 00:00:37.110 -- 00:00:43.156 Earlier today, we released financial results for the quarter ending September 30 2025 00:00:43.156 -- 00:00:45.819 and provided a business update. 00:00:45.819 -- 00:00:51.786 The press release is available on the investor section of our website at innovation bio.com. 00:00:51.786 -- 00:00:55.990 And a recording of this conference call will also be available on our website following 00:00:55.990 -- 00:00:57.676 its completion. 00:00:57.676 -- 00:01:01.823 I'd like to remind you that today's call includes forward-looking statements, including 00:01:01.823 -- 00:01:07.011 statements about the therapeutic and commercial potential of Iptrosi and Sapucitinib, 00:01:07.011 -- 00:01:12.179 the components of our anticipated product revenue, expected milestone payments, 00:01:12.179 -- 00:01:14.763 and our cash runway. 00:01:14.763 -- 00:01:20.452 Because such statements deal with future events and are subject to many risks and uncertainties, 0...